PharmaCell, a spinout of Brightlands Maastricht Health Campus, has been acquired by Lonza.
Lonza, a supplier to the pharmaceutical industry, has acquired PharmaCell, a Netherlands-based cell and gene contract manufacturer spun out of Brightlands Maastricht Health Campus.
The acquisition provides an exit for Limburg Ventures, a venture capital fund that invests in Limburg-based startups, typically spun out of Brightlands Chemelot Campus and Maastricht Health Campus.
Founded in 2005, PharmaCell specialises in autologous cell and gene therapy manufacturing, which uses a patient’s own cells, as opposed to allogeneic therapy, which uses donor cells.
The…
